- Report
- March 2025
- 150 Pages
Global
From €4357EUR$4,850USD£3,797GBP
- Report
- February 2025
- 135 Pages
Global
From €4357EUR$4,850USD£3,797GBP
- Report
- December 2024
- 55 Pages
Global
From €2245EUR$2,499USD£1,956GBP
- Report
- September 2024
- 118 Pages
Global
From €4043EUR$4,500USD£3,523GBP
- Report
- October 2023
- 85 Pages
United States
From €4357EUR$4,850USD£3,797GBP
- Report
- August 2023
- 180 Pages
Global
From €3369EUR$3,750USD£2,936GBP
- Report
- November 2020
- 450 Pages
Global
From €4402EUR$4,900USD£3,836GBP
- Report
- September 2020
- 700 Pages
Global
From €4402EUR$4,900USD£3,836GBP
- Report
- January 2024
- 174 Pages
Global
From €3500EUR$4,173USD£3,157GBP

CAR T Cell therapy is a type of immunotherapy used to treat certain types of cancer. It is a type of gene therapy that uses a patient's own immune cells to recognize and attack cancer cells. The patient's T cells are collected and modified to express a chimeric antigen receptor (CAR) that binds to a specific antigen on the surface of the cancer cells. The modified T cells are then infused back into the patient, where they can recognize and attack the cancer cells.
CAR T Cell therapy has been approved for the treatment of certain types of blood cancers, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). It is also being studied for the treatment of other types of cancer, including solid tumors.
CAR T Cell therapy is a rapidly growing field, with many companies developing and marketing products. Some of the major players in the market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Cellectis. Show Less Read more